Group at a Glance

A world-class developer and manufacturer.

Who We Are

  • World-class developer and manufacturer of high volume disposable medical devices for drug delivery and point-of-care diagnostics
  • Significant product invention and development resources in R&D including a separate Innovations team in Cambridge
  • Bespak is a global market leader in the manufacture of inhaled drug delivery devices for Life Sciences partners
  • Bench-mark capabilities in manufacture of more than 500 million devices per annum in regulated markets
  • High barriers to entry: Intellectual Property, know-how, FDA regulatory approvals and economies of scale
  • Robust finances: profitable, cash generative, low gearing and high dividend payout

Our Strategy

  • Organic revenue growth from:
    • New developments in core respiratory business
    • Diversification into adjacent markets and territories
    • Increasing revenue by capturing more of the value chain
  • Investment in activities in adjacent/complementary technologies/markets
  • Cost efficiency to preserve margins, and remain fit for purpose


Key Products

  • Respiratory: metered dose inhaler valves, dry powder inhalers, integrated dose counters, actuators
  • Injectables: auto-injectors, needle-free injectors
  • Nasal: nasal drug delivery devices
  • Nicotine inhalation devices
  • Other: point-of-care (POC) Diagnostics devices, medical check valves

Market Position

  • A global market leader in respiratory drug delivery
  • Over 500 million devices manufactured annually
  • Nine new products in development pipeline
  • Firm opportunities in attractive new growth market segments

Highlights of the Year

  • Continuing revenue, margin and profit growth with resilient core markets
  • Launch of Chiesi NEXThaler dry powder inhaler
  • Award of multi-year commercial supply contract from Nicoventures
  • Tertiary investment in Atlas Genetics alongside two leading global healthcare companies

Bespak is a leading global player in respiratory drug devices with a strong presence in metered dose inhalers and dry powder inhalers.

  1. Revenue from products and services and operating profit before special items includes the results of both continuing and discontinued operations.

Bespak valve for inhalers

Fast Fact:

Respiratory Market

  • Estimated £272m device sales p.a.
  • Bespak share 22% (estimate)
  • Highly regulated
  • Know how and IP driven
  • Barriers to entry
  • Emerging economy growth